^
BIOMARKER:

BRCA1 mutation

i
Other names: BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
BRCA1 mutation
Ovarian Cancer
rucaparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA1 mutation
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA1 mutation
Ovarian Cancer
BAY 1895344
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C4)
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Solid Tumor
olaparib
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib + durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
rucaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
rucaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
niraparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
niraparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Fallopian Tube Cancer
pamiparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive
:
A1
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Ovarian Cancer
pamiparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
pamiparib
Sensitive
:
A1
BRCA1 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive
:
A2
BRCA1 mutation
Ovarian Cancer
bevacizumab
Resistant
:
A2
BRCA1 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
Breast Cancer
talazoparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
eribulin mesylate
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
pegylated liposomal doxorubicin
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
olaparib
Sensitive
:
A2
BRCA1 mutation
Breast Cancer
olaparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
talazoparib
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
PARP inhibitor
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
doxorubicin hydrochloride
Sensitive
:
A2
BRCA1 mutation
Triple Negative Breast Cancer
paclitaxel
Sensitive
:
A2